Komori
Governance4596Kubota Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Regarding a Material Weakness in Internal Control over Financial Reporting

The Company disclosed that material deficiencies had been identified in the internal controls over financial closing, financial reporting and inventory management, and that its internal control over financial reporting was not effective. Errors were identified in the figures in the initially published financial results summary, and material revisions and corrected disclosures were made in the course of the audit procedures.

Worth reading
89Important
Scored from 1 of 5 sections
Direction
Deterioration
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Contents of this filing

Changes this time

Errors were identified in the figures in the initially published financial results summary, and material revisions and corrected disclosures were made in the course of the audit procedures. The Company disclosed that material deficiencies existed in the internal controls over the financial closing, financial reporting and inventory management processes.

この書類は、機関設計や取締役会の構成そのものは述べていません。上に示したのは、この書類が述べている変更点です。

Contents of this filing
ItemDetails
Changes this timeErrors were identified in the figures in the initially published financial results summary, and material revisions and corrected disclosures were made in the course of the audit procedures. The Company disclosed that material deficiencies existed in the internal controls over the financial closing, financial reporting and inventory management processes.
Items this document does not state (7)
Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The personnel responsible for financial closing procedures, including inventory counts, lacked sufficient expertise and staffing, and a structure had not been established to secure the time required to verify inventory counts, financial closing procedures and the preparation of disclosure documents. In addition, the review function of the Finance and Accounting Department did not operate adequately, and the development and operation of controls to ensure the accuracy of complex accounting treatments and disclosure documents were insufficient. As these deficiencies were identified after the fiscal year-end, corrective measures could not be completed by the fiscal year-end.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding a Material Weakness in Internal Control over Financial Reporting | Kubota Pharmaceutical Holdings Co.,Ltd. (4596) timely disclosure | Komori